Souhaitez-vous accéder aux communiqués récents ?

Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population...

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...

Corporate AI investment across all sectors totaled $252.3 billion in 2024, with mergers and acquisitions up 12.1% and private investment rising 44.5%.

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP,...

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for cell and gene...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION...

Pluristyx and Solesis launch ready-to-use kit combining high-quality pluripotent cells and mRNA technology with proprietary transfection technology

Seamless Therapeutics announces research collaboration and licensing agreement with Eli Lilly for gene therapy for genetic hearing disorders